To compare the efficacy and safety profile of empagliflozin and sitagliptin as an add on therapy to metformin in T2DM patients.
Authors:
Open Access
- 30 July 2025
- journal article
- Published by Independent Medical Trust in The Professional Medical Journal
- Vol. 32 (08) , 940-948
Abstract
Objective: To compare the efficacy and safety and profile of empagliflozin and sitagliptin as an add on therapy to metformin in T2DM patients. Study Design: Randomized Controlled Trial. Period: January to March 2024. Setting: Sheikh Zayed Medical College & Hospital, Rahim Yar Khan. Methods: A total of 280 T2DM patients with inadequate glycemic control on metformin were randomly assigned to receive either empagliflozin or sitagliptin. The primary outcomes included changes in body weight (BW), body mass index (BMI), fasting blood glucose (FBG), HbA1c, systolic and diastolic blood pressure (SBP, DBP), and lipid profile. Secondary outcomes involved monitoring adverse effects throughout the study. Results: After 12 weeks, both groups showed significant reductions in BW and BMI, with empagliflozin showing greater improvements (BW: 92.5±13.5 to 79±14.5 kg, BMI: 29.4±4.2 to 27.5±3.8) compared to sitagliptin (BW: 89±16.6 to 81±12.5 kg, BMI: 28.5±5.6 to 27.3±4.2). Similarly, empagliflozin more effectively reduced FBG (240±60.5 to 130±35.5 mg/dL) and HbA1c (8.35±1.9% to 7.2±1.6%) compared to sitagliptin. Both drugs were well-tolerated with no major adverse effects. Conclusion: Empagliflozin demonstrated superior efficacy and safety compared to sitagliptin as an add-on therapy to metformin in T2DM management.Keywords
This publication has 33 references indexed in Scilit:
- Comparison of the effects of empagliflozin and sitagliptin, as add-on to metformin, on serum levels of asprosin and metabolic parameters in patients with type 2 diabetes mellitusNaunyn-Schmiedeberg's Archives of Pharmacology, 2024
- The effects of sodium-glucose cotransporters type 2 inhibitors on glycemic and extraglycemic laboratory parametersInternational Journal of Diabetes in Developing Countries, 2024
- Diabetes mellitus: Is Pakistan the epicenter of the next pandemic?Chronic Diseases and Translational Medicine, 2023
- Blood pressure-lowering effects of SGLT2 inhibitors and GLP-1 receptor agonists for preventing of cardiovascular events and death in type 2 diabetes: a systematic review and meta-analysisActa Diabetologica, 2023
- IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045Diabetes Research and Clinical Practice, 2022
- SGLT inhibitors on weight and body mass: A meta‐analysis of 116 randomized‐controlled trialsObesity, 2021
- Slope of change in HbA1c from baseline with empagliflozin compared with sitagliptin or glimepiride in patients with type 2 diabetesEndocrinology, Diabetes & Metabolism, 2018
- Comparing SGLT-2 inhibitors to DPP-4 inhibitors as an add-on therapy to metformin in patients with type 2 diabetes: A systematic review and meta-analysisDiabetes & Metabolism, 2018
- SGLT-2 inhibitors: Their pleiotropic propertiesDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2017
- Effects of reducing blood pressure on renal outcomes in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOMEDiabetes & Metabolism, 2017